Sodium–glucose cotransporter 2 inhibitor‐induced changes in body composition and simultaneous changes in metabolic profile: 52‐week prospective <scp>LIGHT</scp> (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study

Abstract

Luseogliflozin treatment brought about favorable changes in body composition and metabolism of moderately obese Japanese type 2 diabetes patients, accompanied by body fat reduction, and minimal muscle and BMC reduction.